Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Slides:

Advertisements

Similar presentations

LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.

Advertisements

Unprovoked DVT in a young patient

Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.

Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism ‘ The PADIS-PE Trial’ Nate Peyton.

TREATMENT OF ACUTE PULMONARY THROMBOEMB0LISM SEYED REZA SEYEDI.MD.

Treatment of VTE Guidelines

Addressing the Challenges in Primary and Secondary Stroke Prevention

Covering the Bases in Cardioversion

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

NOACs for Cancer-Associated Thrombosis:

Anticoagulants in Interventional Cardiology:

Extended Treatment of VTE: Who is the Right Candidate?

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

NOACs In Long-term VTE Treatment: A State Of The Art Review

Long-Term Treatment of VTE: Case Studies

NOACs, AF, and PCI: What Do the Latest Data Suggest?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

NOACs in Clinical Practice: Are They All the Same?

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Pulmonary Embolism Scope of the Problem Massive vs Submassive Pulmonary Embolism.

Oral Anticoagulants in AFa,b A Brief History.

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

A Case Challenge: Anticoagulant Choices for Acute PE

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

New Oral Anticoagulants and VTE Management

VTE Treatment Conventional Approach

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

What Anticoagulant Registries Are Revealing

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Reversal Strategies for VKA: Truths and Misconceptions

Oral Anticoagulation in AF

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Real-World Evidence in VTE

Dos and Don’ts for High-Risk Elderly Patients With AF

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Anticoagulation and Thrombosis Management

The Road to Quality Improvement in HER2-Positive Breast Cancer

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Long-Term Treatment of VTE: Case Studies

A Time for Change for Managing Patients With VTE Who Have Cancer

Cancer-Associated Thrombosis

Managing Pulmonary Embolism Posthospital Discharge

NOAC Studies in VTE AF Studies Superior Outcomes.

Extraordinary Cases in VTE

How I treat cancer-associated venous thromboembolism

Program Goals Background: Anticoagulation in Patients With VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Disease Burden of VTE Phases of VTE Treatment.

At the Crossroads of Coagulation

VKA Reversal and LVADs.

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Potential protocol for the treatment of pulmonary embolism (PE), incorporating direct oral anticoagulants (OACs). Potential protocol for the treatment.

Extraordinary Cases in Stroke Prevention

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Treating Pulmonary Embolism Today

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Clinical Presentations of VTEa,b

NOACs VTE Acute Treatment Trials

Acute VTE Treatment Trials

Considerations for Heparin Lead-in in Pulmonary Embolism

PEITHO Pulmonary Embolism Thrombolysis Study

Phases of VTE Treatment

Incidence of VTE Recurrence

NOACs VTE Extended Treatment Trials

Recommendations for Duration of Anticoagulation

When to Stop Extended Therapy

Anticoagulant Reversal Suggested Protocols

VTE Treatment Trials Fatal vs Major Bleeds

Anticoagulant Treatment of VTE Risk-Benefit of NOAC vs VKA

NOACs in Frail and Elderly Patients

Management of VTE in Cancer Patients

Catheter-Directed Thrombolysis Role in Management of VTE

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)